113 related articles for article (PubMed ID: 12699380)
1. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
J Med Chem; 2003 Apr; 46(9):1617-26. PubMed ID: 12699380
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.
Ako R; Dong D; Wu B
Xenobiotica; 2012 Sep; 42(9):891-900. PubMed ID: 22494439
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.
Sorich MJ; Smith PA; McKinnon RA; Miners JO
Pharmacogenetics; 2002 Nov; 12(8):635-45. PubMed ID: 12439224
[TBL] [Abstract][Full Text] [Related]
4. Establishment of pharmacophore and VolSurf models to predict the substrates of UDP-glucuronosyltransferase1A3.
Wu Z; Zhang X; Ma Z; Wu B
Xenobiotica; 2015; 45(8):653-62. PubMed ID: 25837689
[TBL] [Abstract][Full Text] [Related]
5. In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the VolSurf approach.
Dong D; Wu B
J Pharm Sci; 2012 Sep; 101(9):3531-9. PubMed ID: 22388963
[TBL] [Abstract][Full Text] [Related]
6. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.
Sorich MJ; Miners JO; McKinnon RA; Smith PA
Mol Pharmacol; 2004 Feb; 65(2):301-8. PubMed ID: 14742671
[TBL] [Abstract][Full Text] [Related]
7. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.
Dong D; Ako R; Hu M; Wu B
Xenobiotica; 2012 Aug; 42(8):808-20. PubMed ID: 22385482
[TBL] [Abstract][Full Text] [Related]
8. Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction.
Xu M; Dong P; Tian X; Wang C; Huo X; Zhang B; Wu L; Deng S; Ma X
Pharmacol Res; 2016 Aug; 110():139-150. PubMed ID: 27208893
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates.
Sorich MJ; Smith PA; Miners JO; Mackenzie PI; McKinnon RA
Curr Drug Metab; 2008 Jan; 9(1):60-9. PubMed ID: 18220572
[TBL] [Abstract][Full Text] [Related]
10. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
[TBL] [Abstract][Full Text] [Related]
11. Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.
Wu B; Wang X; Zhang S; Hu M
Pharm Res; 2012 Jun; 29(6):1544-61. PubMed ID: 22302521
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.
Ekins S; Bravi G; Ring BJ; Gillespie TA; Gillespie JS; Vandenbranden M; Wrighton SA; Wikel JH
J Pharmacol Exp Ther; 1999 Jan; 288(1):21-9. PubMed ID: 9862748
[TBL] [Abstract][Full Text] [Related]
13. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
14. Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.
Kaivosaari S; Toivonen P; Aitio O; Sipilä J; Koskinen M; Salonen JS; Finel M
Drug Metab Dispos; 2008 Aug; 36(8):1529-37. PubMed ID: 18474681
[TBL] [Abstract][Full Text] [Related]
15. Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4.
Kubota T; Lewis BC; Elliot DJ; Mackenzie PI; Miners JO
Mol Pharmacol; 2007 Oct; 72(4):1054-62. PubMed ID: 17636046
[TBL] [Abstract][Full Text] [Related]
16. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10.
Kaivosaari S; Toivonen P; Hesse LM; Koskinen M; Court MH; Finel M
Mol Pharmacol; 2007 Sep; 72(3):761-8. PubMed ID: 17576790
[TBL] [Abstract][Full Text] [Related]
17. Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution.
Kato Y; Nakajima M; Oda S; Fukami T; Yokoi T
Drug Metab Dispos; 2012 Feb; 40(2):240-8. PubMed ID: 22028316
[TBL] [Abstract][Full Text] [Related]
18. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
19. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
[TBL] [Abstract][Full Text] [Related]
20. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method.
Sorich MJ; McKinnon RA; Miners JO; Winkler DA; Smith PA
J Med Chem; 2004 Oct; 47(21):5311-7. PubMed ID: 15456275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
